Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Tuesday, The Fly reports. They presently have a $9.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $6.00. HC Wainwright’s price objective would suggest a potential upside of 254.33% from the stock’s current price.
A number of other equities analysts have also issued reports on the stock. LADENBURG THALM/SH SH reissued a “buy” rating and set a $5.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 1st. BidaskClub raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 28th. Craig Hallum initiated coverage on shares of Marinus Pharmaceuticals in a research note on Thursday, April 9th. They set a “buy” rating and a $4.50 price objective on the stock. Cantor Fitzgerald dropped their price objective on shares of Marinus Pharmaceuticals from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 5th. Finally, Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.39.
MRNS opened at $2.54 on Tuesday. Marinus Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $4.83. The firm has a market capitalization of $217.70 million, a PE ratio of -2.35 and a beta of 2.15. The firm has a 50 day moving average of $2.64 and a two-hundred day moving average of $2.21.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Monday, May 4th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.16). As a group, equities research analysts anticipate that Marinus Pharmaceuticals will post -0.78 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Asymmetry Capital Management L.P. acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $766,000. Goldman Sachs Group Inc. grew its stake in Marinus Pharmaceuticals by 14.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 96,366 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 12,437 shares during the period. State Street Corp grew its stake in Marinus Pharmaceuticals by 33.0% in the 1st quarter. State Street Corp now owns 1,217,647 shares of the biopharmaceutical company’s stock valued at $2,472,000 after acquiring an additional 301,788 shares during the period. Oxford Asset Management LLP acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $398,000. Finally, Alyeska Investment Group L.P. grew its stake in Marinus Pharmaceuticals by 99.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,202,012 shares of the biopharmaceutical company’s stock valued at $4,756,000 after acquiring an additional 1,097,461 shares during the period. 81.89% of the stock is currently owned by hedge funds and other institutional investors.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More: What is a Buy-Side Analyst?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.